Dyne Therapeutics (DYN)
(Delayed Data from NSDQ)
$23.70 USD
-1.29 (-5.14%)
Updated Apr 25, 2024 04:00 PM ET
After-Market: $23.70 +0.01 (0.02%) 5:54 PM ET
3-Hold of 5 3
D Value C Growth F Momentum D VGM
Income Statements
Fiscal Year end for Dyne Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 242 | 171 | 150 | 59 | 14 |
Income After Depreciation & Amortization | -242 | -171 | -150 | -59 | -14 |
Non-Operating Income | 6 | 3 | 1 | 0 | -1 |
Interest Expense | 0 | 0 | 0 | 0 | 0 |
Pretax Income | -236 | -168 | -149 | -59 | -15 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -236 | -168 | -149 | -59 | -15 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -236 | -168 | -149 | -59 | -15 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -242 | -168 | -146 | -58 | -14 |
Depreciation & Amortization (Cash Flow) | 1 | 3 | 4 | 1 | 0 |
Income After Depreciation & Amortization | -242 | -171 | -150 | -59 | -14 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 59.68 | 51.98 | 50.90 | 14.40 | NA |
Diluted EPS Before Non-Recurring Items | -3.95 | -3.23 | -2.93 | -4.13 | NA |
Diluted Net EPS (GAAP) | -3.95 | -3.23 | -2.93 | -4.13 | NA |
Fiscal Year end for Dyne Therapeutics, Inc falls in the month of December .
All items in Millions except EPS data.
3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 67.68 | 62.27 | 66.74 | 45.47 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -67.68 | -62.27 | -66.74 | -45.47 |
Non-Operating Income | NA | 1.05 | 2.06 | 1.83 | 1.28 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -66.64 | -60.21 | -64.90 | -44.19 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -66.64 | -60.21 | -64.90 | -44.19 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -66.64 | -60.21 | -64.90 | -44.19 |
Earnings Per Share Data | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | 3/31/23 |
---|---|---|---|---|---|
Average Shares | NA | 61.39 | 61.11 | 59.84 | 56.33 |
Diluted EPS Before Non-Recurring Items | NA | -1.09 | -0.99 | -1.08 | -0.78 |
Diluted Net EPS (GAAP) | NA | -1.10 | -0.99 | -1.08 | -0.78 |